Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Gore

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|November 1, 1990
Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivoA L Jones, J L Millar, B C Millar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2000
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancyR K Gregory, M E Hill, J Moore, et al.
British Journal of Cancer|May 1, 1996
High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic indexM E O'Brien, S Milan, D Cunningham, et al.
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
British Journal of Cancer|November 15, 2007
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensC N Krasner, D S McMeekin, S Chan, et al.
British Journal of Cancer|March 25, 2000
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancerT Eisen, C Boshoff, I Mak, et al.
Cancer|February 15, 1995
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoringR Dummer, M E Gore, B W Hancock, et al.
British Journal of Cancer|January 1, 1994
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant diseaseM T Seymour, J L Mansi, C J Gallagher, et al.
The British Journal of Dermatology|February 16, 2007
Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanomaL A Fearfield, J M G Larkin, A Rowe, et al.
Lancet (London, England)|October 14, 1989
Intensive treatment of multiple myeloma and criteria for complete remissionM E Gore, P J Selby, C Viner, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|November 1, 1990
Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivoA L Jones, J L Millar, B C Millar, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2000
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancyR K Gregory, M E Hill, J Moore, et al.
British Journal of Cancer|May 1, 1996
High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic indexM E O'Brien, S Milan, D Cunningham, et al.
Therapeutic Drug Monitoring|September 1, 1987
Propylene glycol pharmacokinetics and effects after intravenous infusion in humansP A Speth, T B Vree, N F Neilen, et al.
British Journal of Cancer|November 15, 2007
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensC N Krasner, D S McMeekin, S Chan, et al.
British Journal of Cancer|March 25, 2000
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancerT Eisen, C Boshoff, I Mak, et al.
Cancer|February 15, 1995
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoringR Dummer, M E Gore, B W Hancock, et al.
British Journal of Cancer|January 1, 1994
Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant diseaseM T Seymour, J L Mansi, C J Gallagher, et al.
The British Journal of Dermatology|February 16, 2007
Expression of p16, CD95, CD95L and Helix pomatia agglutinin in relapsing and nonrelapsing very thin melanomaL A Fearfield, J M G Larkin, A Rowe, et al.
Lancet (London, England)|October 14, 1989
Intensive treatment of multiple myeloma and criteria for complete remissionM E Gore, P J Selby, C Viner, et al.
Pageof 16